Tags : REFLECTIONS B328-06 study

Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06

 Shots: The REFLECTIONS B328-06 study involves assessing of PF-05280586 vs Rituxan/MabThera (rituximab) in patients with 1L CD20-positive, low tumor burden, follicular lymphoma evaluating its efficacy, safety and immunogenicity, PK and PD The study demonstrated meeting of 1EPs as OS @26 wks. (75.5% vs 70.7%) and PFS@ 1yrs (76.4% vs 81.2%) with similar safety & efficacy […]Read More